Qpfo Why hasn t the U.S. solved the pilot shortage A new study has found that the Pfizer COVID-19 vaccine is less effective at protecting children from the omicron variant.Researchers with the New York State Department of Health found that the vaccine s effectiveness dropped from 68% to 12% in children aged 5 through 11 between Dec. 13 through Jan. 24.But the Centers for Disease Control and Prevention issued a report on Tuesday that stated the vaccine effectiveness in children between the ages of 5 and 11 after its second dose was 46%. Two doses protect against COVID-19鈥揳ssociated emergency department and urgent care enc [url=https://www.stanley-cups.de]stanley cup[/url] ounters among children and adolescents, the CDC report said. However, vaccine effectiveness VE was lower during omicron predominance and decreased with time since vaccination. The public health officials who conducted the s [url=https://www.stanley-cups.co.uk]stanley cup[/url] tu [url=https://www.stanleymugs.us]stanley cup[/url] dy believe it may be due to the lower dosage they received.Kids in that age group were given 10 milligrams, while anyone over 12 received 30 milligrams.The study also found that the effectiveness in children ages 12 to 17 dropped from 66% to 51%.The study results come as New York City is set to end its mask mandate on March 7, CNBC reported.Last week, the Centers for Disease Control and Prev Cbxd Verizon warns customers about text message scam An antiviral pill has shown to be effective in treating COVID-19, according to Phase 2 trial results released late last week.Should those promising results continue in large-scale Phase 3 trials, the drug could become vital in the fight against COVID-19 鈥?a disease that still has few treatment options for those suffering from mild to moderate cases.The drug, molnupiravir, is being produced by Ridgeback Biotherapeutics, which is partnering with Merck in scaling up drug trials. While COVID-19 vaccines attack the spike proteins that give the viral cell their distinctive shape, molnupiravir attacks the reproduction centers of the cells, according to the Wall Street Journal.The goal of the drug is to neuter the contagion so it cant easily spread from person to person 鈥?and results of the drugs Phase 2 trials appears to show its doing just that.According to Ridgeback and Merck, 182 [url=https://www.nikeairjordan.es]jordan[/url] people were given either molnupiravir or a placebo within a week of developing symptoms of COVID-19, and within four days of a positive test. None of those who took the drug twice a day f [url=https://www.skecher.com.de]skechers[/url] or five days were [url=https://www.nikeairforce.es]af1[/url] detected to have any infectious virus through nasal swabs, while 24% of those who received the placebo wer